Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
35A7-(AlPcS4A1)8
- Development stage
- Preclinical
- Lead developer
- Institut du Cancer de Montpellier
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**35A7-(AlPcS4A1)8** is an experimental anti-carcinoembryonic antigen photoimmunotherapy conjugate for cancer photodynamic therapy. It comprises the anti-CEA monoclonal antibody 35A7 covalently linked through a five-carbon sulfonamide spacer to approximately eight molecules of aluminum tetrasulfophthalocyanine, a hydrophilic phthalocyanine photosensitizer. The antibody directs the conjugate to CEA-expressing tumor cells, while light activation of the phthalocyanine payload produces phototoxic reactive oxygen species and inhibits tumor-cell growth. In vitro, the conjugate produced 68% growth inhibition in CEA-expressing SKOv3-CEA-1B9 ovarian carcinoma cells after light exposure. It remains an academic, preclinical research construct with no identified commercial sponsor, marketed product, or clinical development program.
- Other names
- 35A7-(AlPcS(4)A(1))(8)35A7-(AlPcS4A1)8
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on 35A7-(AlPcS4A1)8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 35A7-(AlPcS4A1)8.